Centaurus Biopharma Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Genetastix Corporation

Boe Technology Group Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Chengdu Boe Optoelectronics Technology Co., Ltd.

Thomson Licensing

Adimab, LLC

Primegene (beijing) Co., Ltd.

Mianyang Boe Optoelectronics Technology Co., Ltd.

Other

Beijing Boe Technology Development Co., Ltd.

Beijing Jiaotong University

Thomas Licensing

Nokia Solutions and Networks Oy

Li Zhu

Shaobing Benjamin Hua

Yongxin Han

Yong Peng

Yuandong Hu

Hong Luo

Yanqing Yang

Hui Zhang

Wei Hu

Dengming Xiao

Wei Wu

Shanchun Wang

Yinghui Sun

Zhenhua Zhang

Peng Sun

Jun Wu

Changlong Yuan

Xilei Cao

Bin Wang

Bo Liu

Ling Yang

Na Zhao

Rui Zhao

Xin Tian

Zhi Liang

Xin Li

Yao Huang

Benlian Wang

Xueguang Hao

Jia Liu

Philippe Guillotel

Xi Wang

Zhi Chen

Lang Liu

Hongjiang Xu

Dongfang Yang

He Wang

Qu Qing Chen

Xiao Dong Gu

Hongwei Wang

Jingyi Feng

Qinghe Yang

Xijie Liu

Vesa Pauli Hellgren

Gerald Goermer

Liguang Dai

Xiaowei Duan

Rong Yu

Chao Pan

Hengliang Wang

Erling Feng

Jiheng Yang

Zhao Yang

Fansheng Kong

Xin Gong

Ming Zeng

Shijun Li

Michelle Haynes Pauling

Shaohong Chang

Xiaoxin Li

Shuanghong Wei

Quan Hu

Kui Wang

Charles Chunaming Wang

James T Sheridan

Meng Guo

Chuanyu Zhang

Guang Zhu

Tiantian Wang

Zhicheng Liu

Zanping Wang

Shixin Wang

Weizheng Dong

Xiaohong Kang

Yu-Huei Lin

Dongshu Wang

Xiankai Liu

Changxin Dong

Zujun Yu

Siyu Lin

Mingzhao Hao

Zhehui Peng

Qianqian Zhao

Zhaobai Zhong

Yangjian Liu

Xiaofeng Zhai

A pixel driving circuit, including: a driving transistor, and first and second energy storage elements; a first reset sub-circuit configured to write an initialization voltage signal to a third node in response to a first reset signal; a second reset sub-circuit configured to, in response to a second reset signal, turn it conductive between a gate of the driving transistor and a fourth node and reset the two; a data writing sub-circuit configured to write a data voltage signal to the second energy storage element in response to a scanning signal; and a light emitting control sub-circuit configured to turn it conductive between a first electrode of the driving transistor and a power supply terminal in response to a first light emitting control signal, and transmit the data voltage signal to the gate of the driving transistor in response to a second light emitting control signal.

Pixel driving circuit, driving method thereof, display substrate, and display apparatus

Pyrazolopyrazine derived compounds as represented by general formulas (AI) and (I) or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an isotopic marker or an isomer thereof. Provided are a pharmaceutical composition comprising same and use of the compounds and the pharmaceutical composition in the preparation of medicaments for treating JAK kinase-mediated diseases. The compounds and pharmaceutical composition thereof provided have significant JAK kinase inhibitory activity, and in particular, have relatively high Tyk2 kinase inhibitory activity and selectivity for JAK2, and therefore have a very promising application potential.

Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof

A pixel circuit and a driving method therefor, and a display panel. The pixel circuit includes a driving circuit, a data writing circuit, a compensation storage circuit, a first light-emitting control circuit and a second light-emitting control circuit. The driving circuit includes a control end, a first end, and a second end, and is configured to control a driving current which flows through the first end and the second end and which is used for driving a light-emitting element to emit light; the data writing circuit is connected to a first scanning signal line and is configured to, in response to a first scanning signal provided by the first scanning signal line, write a data signal into the first end of the driving circuit; the data writing circuit and the first light-emitting control circuit repel one another in a connected state under the control of the first scanning signal.

Pixel circuit and driving method therefor, and display panel

Provided is a quinolyl-containing compound as shown in general formula (I) or (II) or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an isotopic label, or an isomer thereof, and further provided are a pharmaceutical composition comprising the compound and use of the compound and the pharmaceutical composition. The provided compound has a dual molecule function, can serve as multi-target inhibitors of novel tyrosine kinase/histone deacetylase, can simultaneously achieve the effect of two inhibitors, has excellent biological activity and pharmacokinetic properties, and has the application potential particularly in the field of treatment of tumors.

Quinolyl-containing compound and pharmaceutical composition, and use thereof

A pixel circuit and a driving method therefor and a display panel are provided. The pixel circuit includes a driving circuit, a data writing circuit, a storage circuit, and a first reset circuit; the driving circuit includes a control terminal, a first terminal, and a second terminal, and is configured to control a driving current flowing through the first terminal and the second terminal for driving a light-emitting element to emit light; the data write circuit is configured to write a data signal into the control terminal of the driving circuit; the storage circuit is configured to store the data signal; the first reset circuit is configured to apply a first initialization voltage to the control terminal of the driving circuit; the driving circuit and the data write circuit each include an N-type thin film transistor; and the first reset circuit includes an N-type oxide thin film transistor.

Pixel circuit and driving method therefor and display panel

The present invention discloses aimmunogenic protein and its composition and application. This invention provides a protein, comprising 39 amino acids of the N-terminal α-helix part of the Ata protein transport functional domain ofand an adjuvant protein; amino acid sequence of said 39 amino acids of the N-terminal α-helix part of the Ata protein transport functional domain ofis shown as the 127-165amino acid residues of SEQ ID NO:2. In present invention the 39 amino acids of the N-terminal α-helix part of surface protein Ata (trimeric autotransporter) of, was took to fuse with CTB, and express in BL21. The protein was purified by a nickel column, and used to intraperitoneally immunize mouses by 2.5 μg/mouse. Its immunogenicity and immunoprotection was verified through the animal experiments, which proves it has a good effect of anti-infection of

immunogenic protein and composition and application thereof

A pixel driving circuit includes: a data writing circuit, a compensation control circuit, a light emission control circuit, a voltage regulation circuit, a driving transistor, the compensation control circuit is connected with the driving transistor at a first node, the compensation control circuit is connected with the data writing circuit at a second node, the compensation control circuit, the light emission control circuit, the voltage regulation circuit are connected with the driving transistor at a third node; the compensation control circuit obtains a threshold voltage of the driving transistor, writes a third voltage into the second node, and writes a light emission voltage into the first node according to a variation in a voltage at the second node and the threshold voltage; the voltage regulation circuit maintains a voltage at the third node stable during the compensation control circuit writing the light emission voltage into the first node.

Pixel driving circuit and driving method thereof, display substrate and display device

The present invention provides a compound as represented by formula (1) or a pharmaceutically acceptable salt, a solvate, an active metabolite, a polymorph, an isotope label, an isomer or a prodrug thereof. The present invention also provides a pharmaceutical composition containing the same and the use of the compound and the pharmaceutical composition in preparation of drugs for treating tyrosine kinase-mediated diseases. The compound and the pharmaceutical composition comprising same provided by the present disclosure have significant tyrosine kinase inhibitory activity, can overcome tumor drug resistance, and break through blood-brain barrier, also have excellent pharmacokinetic properties and excellent oral bioavailability, and can be administered in a small dosage, thereby reducing treatment costs and possible side effects to a patient. Thus, the application potential is very great.

Diaryl macrocyclic compound and pharmaceutical composition, and use thereof

Provided is a display panel, including: a substrate including a display region and a peripheral region; a first dam; a planarization layer disposed within the first dam, wherein an edge of a first side of the planarization layer includes a first segment boundary and a second segment boundary that are connected; a packaging layer covering the planarization layer; and a touch layer disposed on the packaging layer, wherein the touch layer includes a touch electrode pattern and a touch signal line traveling through the first segment boundary; wherein the packaging layer includes an organic layer, and a distance between an edge of the organic layer, on a same side of the display region as the first side of the planarization layer, and the first segment boundary of the planarization layer is greater than a distance between the edge of the organic layer and the second segment boundary.

Display panel

Embodiments of the present disclosure provide a method and a device for cooperative control of multiple trains. The method includes: S1, establishing a train dynamic model of urban rail transit; S2, modeling a train control system of urban rail transit based on train-to-train communication; S3, constructing, according to the dynamic model and a control system model, an optimized control target which comprehensively considers distance convergence and speed convergence of train formation; and S4, cooperatively controlling, on the basis of an artificial potential field method and Kalman filtering and according to the optimized control target, the multiple trains. The present disclosure is capable of effectively shortening a train headway.

Method and device for cooperative control of multiple trains

Provided is a display panel, including: a substrate comprising: a display region, a peripheral region and a pad region; a first dam; a planarization layer disposed within the first dam, wherein a first groove is defined between the first dam and the planarization layer, and wherein an edge of a first side of the planarization layer comprises a first segment boundary and a second segment boundary that are connected; a packaging layer covering the planarization layer; and a touch layer disposed on the packaging layer, wherein the touch layer comprises a touch signal line and a touch electrode pattern, the a touch electrode pattern being electrically connected to a pad in the pad region by the touch signal line which travels through the first segment boundary; wherein the packaging layer comprises an organic layer, an edge of the organic layer being disposed in the first groove.

Display panel, method for manufacturing the same and display device

An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer. 

Iridinesulfonamide compound and use method thereof

Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers. 

Sultam compound and application method thereof

The invention provided a method for preparing a bacterial polysaccharide-modified recombinant fusion protein and use of the bacterial polysaccharide-modified recombinant fusion protein. The method comprises: co-expressing a recombinant fusion protein and theO-oligosaccharyltransferase PglL in an O-antigen ligase gene-defective bacterium, and linking a polysaccharides endogenous or exogenous for the bacterium to the recombinant fusion protein by the O-oligosaccharyltransferase PglL, to obtain the bacterial polysaccharide-modified recombinant fusion protein. The protein can be used for preparing antibodies against bacterial polysaccharides and vaccines.

Method for preparing bacterial polysaccharide-modified recombinant fusion protein and use of the protein

Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals. 

Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor

Growing community of inventors

Beijing, China

Li Zhu